Allison Clemens
April
ababaabhay
achoi2392
adhoward1

2025 PACUPrep BCCCP Preparatory Course Endocarditis Foundational Principles: Epidemiology, Pathophysiology, and Risk Factors

Lesson 65, Topic 1

In Progress

← Previous

Foundational Principles: Epidemiology, Pathophysiology, and Risk Factors

Lesson Progress

0% Complete

Infective Endocarditis: Epidemiology, Pathophysiology, and Risk Factors

Foundational Principles: Epidemiology, Pathophysiology, and Risk Factors of Infective Endocarditis

Learning Objective

Describe the epidemiology, pathophysiology, and risk factors of infective endocarditis (IE) in critically ill patients.

1. Epidemiology and Incidence

Rationale: The incidence of infective endocarditis (IE) is 3–7 per 100,000 person-years in the general population but can be five-fold higher in ICU settings due to invasive devices, comorbidities, and healthcare exposure.

Incidence and Acquisition

General Population: 3–7 cases per 100,000 person-years.
ICU Cohorts: Incidence can rise to 35 cases per 100,000 person-years.
Acquisition Shift: There is a decreasing trend in community-acquired IE (often from viridans streptococci) and a rise in healthcare-associated IE, which now accounts for ≥30% of cases, with Staphylococcus aureus being the predominant pathogen.

Mortality and Risk Predictors

Mortality: The mortality rate for S. aureus IE in the ICU can be as high as 40%. For prosthetic valve endocarditis (PVE), mortality exceeds 25%.
Predictors of Poor Outcome: Factors associated with ICU admission and high mortality include vegetation size >10 mm, presence of heart failure, embolic events (to the brain, lung, or spleen), advanced age, a high SOFA score, and delayed surgical intervention.

Clinical Pearl: S. aureus Bacteremia

Any ICU patient with persistent Staphylococcus aureus bacteremia warrants prompt echocardiographic evaluation to rule out infective endocarditis, as it is a common and devastating complication.

Clinical Pearl: Indwelling Devices

The presence of prosthetic valves and indwelling central venous or hemodialysis catheters markedly amplifies the risk of developing IE. These devices serve as a nidus for infection.

2. Pathophysiology of Vegetation Formation

Rationale: Vegetations arise when endothelial injury triggers sterile platelet-fibrin thrombi, known as nonbacterial thrombotic endocarditis (NBTE), which then serve as scaffolds for bacterial adhesion, biofilm formation, and eventual systemic embolization.

Figure 1: Pathophysiology of Vegetation Formation. The process begins with endothelial damage, leading to a sterile thrombus that becomes colonized during bacteremia, ultimately forming a mature, friable vegetation.

Embolic and Immunologic Sequelae

Embolization: Fragmentation of the vegetation can lead to septic emboli, causing infarcts in distant organs like the brain, kidneys, spleen, and lungs.
Immune Complex Deposition: Circulating immune complexes can deposit in tissues, leading to complications such as glomerulonephritis and classic peripheral stigmata like Osler’s nodes.
Periannular Invasion: The infection can extend beyond the valve leaflet into surrounding tissue, causing abscesses, fistulas, and conduction system disturbances.

Clinical Pearl: Biofilm Challenge

Bacteria embedded within a biofilm matrix are protected from host defenses and have significantly higher minimum inhibitory concentrations (MICs), often by a factor of 1,000. This necessitates prolonged courses of high-dose bactericidal antibiotics for effective treatment.

3. Impact of Chronic Comorbidities

Rationale: Pre-existing structural heart disease, the presence of prosthetic material, and various systemic illnesses amplify IE risk, alter the clinical presentation, and complicate management.

Cardiac Conditions

Native Valvular Disease: Includes rheumatic, degenerative, or congenital abnormalities that create turbulent blood flow.
Prosthetic Valves: Prosthetic valve endocarditis (PVE) carries a high mortality rate (up to 40%). Early transesophageal echocardiography (TEE) is recommended.
Cardiac Implantable Electronic Devices (CIEDs): Infections involving pacemakers or defibrillators often mandate complete hardware removal for source control.

Systemic Diseases and Catheter Risk

Diabetes Mellitus: Associated with impaired neutrophil function and poor tissue healing.
Chronic Kidney Disease/Hemodialysis: Recurrent catheter-related bacteremia provides a frequent portal of entry for pathogens.
Immunosuppression: Patients may present with atypical features and muted inflammatory markers, potentially delaying diagnosis.
Catheter-Related Risk: Central venous and dialysis catheters are major portals of entry for S. aureus and enterococci. Adherence to chlorhexidine antisepsis and catheter-care bundles is critical for prevention.

Clinical Pearl: Prosthetic Valve Fever

In any patient with a prosthetic valve who presents with a fever of unknown origin, a transesophageal echocardiogram (TEE) should be performed within 48 hours to assess for PVE.

4. Role of Social Determinants of Health

Rationale: Socioeconomic factors—including oral hygiene, health literacy, substance use, and access to care—significantly modulate IE risk and the timeliness of diagnosis and treatment.

Access to Care and Oral Health

Medication and Care Access: Financial barriers can prevent timely access to echocardiography, prolonged antibiotic courses, and essential specialist follow-up. Low health literacy may lead to poor adherence.
Oral Health: Periodontitis and poor dental hygiene are sources of frequent transient bacteremia. Limited access to dental care increases the risk of IE caused by viridans group streptococci.

Substance Use

Intravenous (IV) Drug Use: A primary risk factor for right-sided IE (typically tricuspid valve) and septic pulmonary emboli.
Barriers to Care: Systemic barriers to harm reduction services and sterile injection equipment perpetuate the cycle of infection in this vulnerable population.

Clinical Pearl: Pre-Surgical Coordination

Prior to elective valve surgery, it is crucial to implement dental clearance protocols and provide education on oral hygiene. Post-discharge, coordination with social services is vital to optimize follow-up and treatment adherence in underserved patients.

5. Clinical Implications and Risk Stratification

Rationale: The modified Duke criteria and established risk scores are essential tools that guide the diagnosis of IE, determine the urgency of intervention, and inform prophylaxis strategies.

Modified Duke Criteria

This scoring system is the cornerstone of diagnosis. A definitive diagnosis is made based on a combination of major and minor clinical, microbiological, and imaging findings.

Modified Duke Criteria for the Diagnosis of Infective Endocarditis
Criterion Type	Description	Diagnosis of “Definite IE”
Major Criteria	Positive blood cultures for typical IE organisms. Echocardiographic evidence of endocardial involvement (vegetation, abscess, new valve regurgitation).	2 Major Criteria 1 Major + 3 Minor Criteria 5 Minor Criteria
Minor Criteria	Predisposing condition or IV drug use Fever ≥38°C (100.4°F) Vascular phenomena (e.g., emboli, Janeway lesions) Immunologic phenomena (e.g., Osler’s nodes, glomerulonephritis) Positive blood culture not meeting major criteria

Prophylaxis and Early Recognition

High-Risk Groups for Prophylaxis: Includes patients with prosthetic valves, a prior history of IE, and certain complex congenital heart diseases.
Standard Prophylaxis: A single dose of amoxicillin 2g (or clindamycin for penicillin-allergic patients) taken 30–60 minutes before high-risk dental procedures.
ICU Recognition Triggers: A high index of suspicion should be triggered by a new heart murmur, persistent bacteremia despite appropriate antibiotics, or new embolic phenomena. Consider embedding echocardiography prompts in sepsis order sets.

Clinical Pearl: The Value of Repeat Imaging

A single negative transesophageal echocardiogram (TEE) does not definitively exclude IE in high-risk patients. If clinical suspicion remains high, the TEE should be repeated in 7–10 days, as early, small vegetations may have been missed.

References

Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132(15):1435–1486.
Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293(24):3012–3021.
Moreillon P, Que YA, Bayer AS. Pathogenesis of streptococcal and staphylococcal endocarditis. Infect Dis Clin North Am. 2002;16(2):297–318.
Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med. 1994;96(3):200–209.
Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010;121(3):458–477.
Wilson WR, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association. Circulation. 2007;116(15):1736–1754.
Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36(44):3075–3128.
Iversen K, Ihlemann N, Gill SU, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med. 2019;380(5):415–424.
Lockhart PB, Brennan MT, Thornhill M, et al. Poor oral hygiene as a risk factor for infective endocarditis-related bacteremia. J Am Dent Assoc. 2009;140(10):1238–1244.
Dayer MJ, Jones S, Prendergast B, et al. Incidence of infective endocarditis in England, 2000–13: a secular analysis. Lancet. 2015;385(9974):1219–1228.

2025 PACUPrep BCCCP Preparatory Course

Pulmonary

Participants 432